PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer’s question

Overview of attention for article published in European Journal of Nuclear Medicine and Molecular Imaging, October 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 16,556 followers.

RT @LysaLymphoma: How the final decision is taken by independant central review in Hodgkin trial https://t.co/9UeuUMKTj7

RT @LysaLymphoma: How the final decision is taken by independant central review in Hodgkin trial https://t.co/9UeuUMKTj7

RT @hematosantpau: ¿Cómo evaluar el #PET en la era de los inhibidores del #Checkpoint del linfo T en #hodgkin? @sehh_es https://t.co/KGpMpV…

RT @hematosantpau: ¿Cómo evaluar el #PET en la era de los inhibidores del #Checkpoint del linfo T en #hodgkin? @sehh_es https://t.co/KGpMpV…

¿Cómo evaluar el #PET en la era de los inhibidores del #Checkpoint del linfo T en #hodgkin? @sehh_es https://t.co/KGpMpVStEK

How the final decision is taken by independant central review in Hodgkin trial https://t.co/9UeuUMKTj7